2015 Pharma Companies RNA Small Molecule 
Dark Matter Blog
JUNE 21, 2023
Since our company’s founding in 2015, we have taken the long view and been singularly focused on building an extremely flexible and broadly applicable platform that can develop a host of RNA‑targeted small molecules (rSMs) to deliver precision medicines for dozens of targets that have been out of reach for conventional approaches.
Drug Discovery World
JANUARY 3, 2023
In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL platforms, and several service providers offer DEL capabilities to companies that outsource their DEL activities.
Expert insights. Personalized for you.
52 
Let's personalize your content